Status:
UNKNOWN
A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors
Lead Sponsor:
Betta Pharmaceuticals Co., Ltd.
Conditions:
Metastasis, Neoplasm
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is an open-labe Phase I study of BPI-28592 for the treatment of patients with solid tumors
Eligibility Criteria
Inclusion
- Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor
- At least 18 years of age
- Measurable or evaluable disease
- Adequate organ function as defined per protocol
Exclusion
- Symptomatic or unstable brain metastases
- Pregnancy or lactation
- Other protocol specified criteria
Key Trial Info
Start Date :
March 22 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05302843
Start Date
March 22 2021
End Date
December 31 2023
Last Update
March 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine
Hangzhou, Zhejiang, China